Arena Pharmaceuticals (NASDAQ:ARNA) has dosed the first participant in the ELEVATE UC 12 global Phase 3 trial evaluating etrasimod, as the potential treatment of moderately to severely active ulcerative colitis (UC).
ELEVATE UC 12 will assess the efficacy and safety of etrasimod 2 mg once-daily in subjects with moderately to severely active UC. The primary objective of this trial is clinical remission at 12 weeks (similar to the Phase 2 OASIS trial)
“This is a significant milestone for Arena as the progress confirms that the ELEVATE UC registrational program, including ELEVATE UC 12 and UC 52 trials, remains on track for data by year-end 2021.” said Chris Cabell EVP, Head of R&D, and Chief Medical Officer.
Etrasimod is an orally available next-generation sphingosine 1-phosphate receptor modulator. Selected binding to subtype S1PR1 leads to anti-inflammatory activity by its (theorized) interference with the migration of a specific subset of activated lymphocytes to sites of inflammation
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.